ETF Holdings Breakdown of PRME

Stock Name	Prime Medicine, Inc. Common Stock
Ticker	PRME(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US74168J1016

News associated with PRME

Wells Fargo & Company MN Lowers Holdings in Prime Medicine, Inc. (NYSE:PRME): Wells Fargo & Company MN trimmed its position in shares of Prime Medicine, Inc. (NYSE:PRME – Free Report) by 43.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 96,181 shares of the company’s stock after selling 75,287 shares during the period. Wells Fargo & Company MN’s holdings in Prime Medicine were worth $281,000 as […] - 2025-05-07 07:24:56
XTX Topco Ltd Makes New Investment in Prime Medicine, Inc. (NYSE:PRME): XTX Topco Ltd purchased a new position in Prime Medicine, Inc. (NYSE:PRME – Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 14,466 shares of the company’s stock, valued at approximately $42,000. Other hedge funds have also bought and sold shares of the […] - 2025-05-02 08:10:54
Prime Medicine, Inc. (NYSE:PRME) Shares Acquired by Walleye Capital LLC: Walleye Capital LLC increased its position in shares of Prime Medicine, Inc. (NYSE:PRME – Free Report) by 272.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 403,739 shares of the company’s stock after purchasing an additional 295,365 shares […] - 2025-04-21 08:16:56
Prime Medicine, Inc. (NYSE:PRME) Receives $13.38 Consensus Price Target from Analysts: Shares of Prime Medicine, Inc. (NYSE:PRME – Get Free Report) have been given a consensus recommendation of “Buy” by the nine analysts that are covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year […] - 2025-04-18 05:28:53
Critical Review: Prime Medicine (NYSE:PRME) and Pluri (NASDAQ:PLUR): Pluri (NASDAQ:PLUR – Get Free Report) and Prime Medicine (NYSE:PRME – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings. Risk & Volatility Pluri has a beta of […] - 2025-04-15 05:44:49
Prime Medicine (NYSE:PRME) Receives “Outperform” Rating from Wedbush: Wedbush reaffirmed their outperform rating on shares of Prime Medicine (NYSE:PRME – Free Report) in a research note published on Tuesday,RTT News reports. The firm currently has a $13.00 price target on the stock, up from their prior price target of $12.00. A number of other research firms have also recently commented on PRME. StockNews.com […] - 2025-03-19 06:40:51
Reviewing Prime Medicine (NYSE:PRME) & Bio-Techne (NASDAQ:TECH): Prime Medicine (NYSE:PRME – Get Free Report) and Bio-Techne (NASDAQ:TECH – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk. Risk & Volatility Prime Medicine has a beta of […] - 2025-02-28 07:00:48
Prime Medicine, Inc. (NYSE:PRME) Receives $13.13 Average Target Price from Brokerages: Prime Medicine, Inc. (NYSE:PRME – Get Free Report) has been assigned an average rating of “Buy” from the ten research firms that are currently covering the stock, MarketBeat reports. Nine analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target […] - 2025-02-27 06:09:13
Prime Medicine (NYSE:PRME) versus Qiagen (NYSE:QGEN) Financial Review: Prime Medicine (NYSE:PRME – Get Free Report) and Qiagen (NYSE:QGEN – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings. Insider & Institutional Ownership 70.4% of Prime Medicine shares […] - 2025-02-19 06:12:57
Prime Medicine (NYSE:PRME) Upgraded at StockNews.com: StockNews.com upgraded shares of Prime Medicine (NYSE:PRME – Free Report) to a sell rating in a report released on Tuesday. A number of other equities research analysts have also recently issued reports on PRME. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Prime Medicine in a research note […] - 2025-02-14 08:32:51
Sumitomo Mitsui Trust Group Inc. Sells 100,275 Shares of Prime Medicine, Inc. (NYSE:PRME): Sumitomo Mitsui Trust Group Inc. lessened its position in shares of Prime Medicine, Inc. (NYSE:PRME – Free Report) by 3.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,090,180 shares of the company’s stock after selling 100,275 shares during the […] - 2025-02-13 10:16:49
China Universal Asset Management Co. Ltd. Buys 4,725 Shares of Prime Medicine, Inc. (NYSE:PRME): China Universal Asset Management Co. Ltd. grew its stake in shares of Prime Medicine, Inc. (NYSE:PRME – Free Report) by 20.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 27,811 shares of the company’s stock after acquiring an additional 4,725 shares during the quarter. […] - 2025-02-04 09:14:55
Brokerages Set Prime Medicine, Inc. (NYSE:PRME) PT at $13.13: Shares of Prime Medicine, Inc. (NYSE:PRME – Get Free Report) have received a consensus rating of “Buy” from the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month […] - 2025-02-04 08:36:56
Prime Medicine (NYSE:PRME) and Windtree Therapeutics (NASDAQ:WINT) Critical Survey: Prime Medicine (NYSE:PRME – Get Free Report) and Windtree Therapeutics (NASDAQ:WINT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations. Insider & Institutional Ownership 70.4% of Prime […] - 2025-02-04 06:46:59

PRME institutional holdings

The following institutional investment holdings of PRME have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 58,689 USD 77,469

2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 58,689 USD 77,469 -7.6%

Total = 117,378 USD 154,938
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	58,689	USD 77,469
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	58,689	USD 77,469 -7.6%
Total =	117,378	USD 154,938

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.